CY1123647T1 - Διαμορφωση της ανοσιας ογκων - Google Patents
Διαμορφωση της ανοσιας ογκωνInfo
- Publication number
- CY1123647T1 CY1123647T1 CY20201101173T CY201101173T CY1123647T1 CY 1123647 T1 CY1123647 T1 CY 1123647T1 CY 20201101173 T CY20201101173 T CY 20201101173T CY 201101173 T CY201101173 T CY 201101173T CY 1123647 T1 CY1123647 T1 CY 1123647T1
- Authority
- CY
- Cyprus
- Prior art keywords
- modulation
- tumor immunity
- antagonist
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Περιγράφονται μέθοδοι αγωγής υπερπλαστικών διαταραχών. Ειδικότερα, παρέχεται αγωγή συνδυασμού με έναν αγωνιστή GITR και έναν ανταγωνιστή PD-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361867976P | 2013-08-20 | 2013-08-20 | |
PCT/US2014/051402 WO2015026684A1 (en) | 2013-08-20 | 2014-08-18 | Modulation of tumor immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123647T1 true CY1123647T1 (el) | 2022-03-24 |
Family
ID=51493040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201101173T CY1123647T1 (el) | 2013-08-20 | 2020-12-11 | Διαμορφωση της ανοσιας ογκων |
Country Status (43)
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
AU2014364601A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
KR101923326B1 (ko) | 2014-06-06 | 2018-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
JP6913682B2 (ja) | 2015-07-23 | 2021-08-04 | インヒブリックス, インコーポレイテッド | 多価および多重特異性gitr結合融合タンパク質 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
TN2017000554A1 (en) | 2015-07-29 | 2019-04-12 | Novartis Ag | Novel combination for use in the treatment of cancer |
GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合 |
MY189018A (en) | 2015-11-18 | 2022-01-19 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
EP3377532B1 (en) | 2015-11-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
JP6993699B2 (ja) | 2016-01-11 | 2022-02-03 | ウニヴェルズィテート・ツューリヒ | ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質 |
TWI742054B (zh) * | 2016-03-08 | 2021-10-11 | 美商健生生物科技公司 | Gitr抗體,方法及用途 |
TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
ES2905823T3 (es) | 2016-05-20 | 2022-04-12 | Biohaven Therapeutics Ltd | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres |
CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
AU2017278193B9 (en) | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
JP2019519536A (ja) | 2016-07-01 | 2019-07-11 | ファイブ プライム セラピューティクス, インコーポレイテッド | Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法 |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
IL296127A (en) | 2016-07-22 | 2022-11-01 | Dana Farber Cancer Inst Inc | Antibodies to the glucocorticoid-induced tumor necrosis factor receptor and methods of using them |
EA201990672A1 (ru) | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CN113896792A (zh) | 2017-05-12 | 2022-01-07 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
KR20200006115A (ko) * | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
KR20200041834A (ko) | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER |
CR20190593A (es) | 2017-06-22 | 2020-05-10 | Novartis Ag | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas |
KR20200022447A (ko) | 2017-06-27 | 2020-03-03 | 노파르티스 아게 | 항-tim-3 항체의 투여 요법 및 그의 용도 |
AU2018302283A1 (en) | 2017-07-20 | 2020-02-06 | Novartis Ag | Dosage regimens of anti-LAG-3 antibodies and uses thereof |
MX2020003856A (es) | 2017-10-13 | 2020-08-13 | Harpoon Therapeutics Inc | Proteinas de union a antigenos de maduracion de celulas b. |
JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍処置法 |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
WO2019184909A1 (zh) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍を処置する方法 |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
JP2021525071A (ja) | 2018-05-31 | 2021-09-24 | ノバルティス アーゲー | B型肝炎抗体 |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CN112512578A (zh) | 2018-06-01 | 2021-03-16 | 诺华股份有限公司 | 结合cd123和cd3的双特异性抗体的给药 |
FI3820573T3 (fi) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
WO2020053742A2 (en) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anti-hla-hbv peptide antibodies |
EP3852524B1 (en) | 2018-09-20 | 2023-06-28 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
WO2020086406A2 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
EP3880247A4 (en) | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | BISPECIFIC ANTIBODIES TO ACTIVATE IMMUNE CELLS |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
AU2019406840A1 (en) | 2018-12-21 | 2021-06-03 | Novartis Ag | Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
EP3898674A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
US20230058489A1 (en) | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
WO2021171264A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosing of a bispecific antibody that binds cd123 and cd3 |
BR112022017156A2 (pt) | 2020-03-06 | 2022-11-08 | Regeneron Pharma | Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo |
CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
WO2022003693A1 (en) * | 2020-07-02 | 2022-01-06 | Biolojic Design Ltd. | Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
WO2022148279A1 (zh) * | 2021-01-08 | 2022-07-14 | 苏州丁孚靶点生物技术有限公司 | 药物产品及其用途 |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US7670604B2 (en) | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
EP1766396B1 (en) | 2004-06-07 | 2010-08-11 | Ramot at Tel-Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
ATE508204T1 (de) | 2004-07-15 | 2011-05-15 | Univ Wien Tech | Verfahren für den nachweis von fusarium graminearum |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
JP2008278814A (ja) * | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
EP2350129B1 (en) * | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
MX338825B (es) * | 2008-10-02 | 2016-05-03 | Emergent Product Dev Seattle | Proteinas de enlace a objetivos multiples de antagonistas de cd86. |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
EP2473519A4 (en) * | 2009-09-03 | 2013-04-10 | Univ Illinois | TREATMENT OF DISEASES INDUCED BY BACTERIAL EXOTOXINS |
US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
CN104334184B (zh) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AU2017278193B9 (en) | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
-
2014
- 2014-08-11 AR ARP140103008A patent/AR097306A1/es unknown
- 2014-08-15 TW TW103128185A patent/TWI660737B/zh not_active IP Right Cessation
- 2014-08-18 SI SI201431723T patent/SI3036256T1/sl unknown
- 2014-08-18 CN CN201480046383.4A patent/CN105492463B/zh not_active Expired - Fee Related
- 2014-08-18 US US14/912,733 patent/US10188729B2/en active Active
- 2014-08-18 CA CA2921561A patent/CA2921561C/en not_active Expired - Fee Related
- 2014-08-18 AU AU2014309163A patent/AU2014309163A1/en not_active Abandoned
- 2014-08-18 KR KR1020167004045A patent/KR101979070B1/ko active IP Right Grant
- 2014-08-18 SG SG10201800389YA patent/SG10201800389YA/en unknown
- 2014-08-18 BR BR112016003394A patent/BR112016003394A2/pt not_active Application Discontinuation
- 2014-08-18 PT PT147614606T patent/PT3036256T/pt unknown
- 2014-08-18 TN TN2016000041A patent/TN2016000041A1/en unknown
- 2014-08-18 KR KR1020187009892A patent/KR20180038081A/ko not_active Application Discontinuation
- 2014-08-18 MD MDA20160024A patent/MD20160024A2/ro not_active Application Discontinuation
- 2014-08-18 EP EP14761460.6A patent/EP3036256B1/en not_active Revoked
- 2014-08-18 GE GEAP201414103A patent/GEP20186905B/en unknown
- 2014-08-18 MX MX2016002271A patent/MX360789B/es active IP Right Grant
- 2014-08-18 RS RS20201551A patent/RS61228B1/sr unknown
- 2014-08-18 LT LTEP14761460.6T patent/LT3036256T/lt unknown
- 2014-08-18 WO PCT/US2014/051402 patent/WO2015026684A1/en active Application Filing
- 2014-08-18 MA MA38814A patent/MA38814B2/fr unknown
- 2014-08-18 PL PL14761460.6T patent/PL3036256T3/pl unknown
- 2014-08-18 SG SG11201600990VA patent/SG11201600990VA/en unknown
- 2014-08-18 ES ES14761460T patent/ES2835727T3/es active Active
- 2014-08-18 UA UAA201602684A patent/UA118453C2/uk unknown
- 2014-08-18 AP AP2016009073A patent/AP2016009073A0/xx unknown
- 2014-08-18 JP JP2016536340A patent/JP6383419B2/ja not_active Expired - Fee Related
- 2014-08-18 HU HUE14761460A patent/HUE052967T2/hu unknown
- 2014-08-18 EP EP20190848.0A patent/EP3770175A3/en not_active Withdrawn
- 2014-08-18 EA EA201690429A patent/EA201690429A1/ru unknown
- 2014-08-18 MY MYPI2016000312A patent/MY187075A/en unknown
- 2014-08-18 PE PE2016000270A patent/PE20160225A1/es unknown
- 2014-08-18 DK DK14761460.6T patent/DK3036256T3/da active
- 2014-08-20 JO JOP/2014/0253A patent/JO3553B1/ar active
-
2016
- 2016-02-04 IL IL243986A patent/IL243986B/en active IP Right Grant
- 2016-02-05 NI NI201600025A patent/NI201600025A/es unknown
- 2016-02-12 DO DO2016000049A patent/DOP2016000049A/es unknown
- 2016-02-15 PH PH12016500309A patent/PH12016500309A1/en unknown
- 2016-02-16 CL CL2016000354A patent/CL2016000354A1/es unknown
- 2016-02-19 CR CR20160086A patent/CR20160086A/es unknown
- 2016-02-19 SV SV2016005158A patent/SV2016005158A/es unknown
- 2016-02-19 GT GT201600036A patent/GT201600036A/es unknown
- 2016-03-18 EC ECIEPI201611533A patent/ECSP16011533A/es unknown
- 2016-07-08 HK HK16108016.5A patent/HK1219960A1/zh unknown
-
2017
- 2017-07-06 JP JP2017132379A patent/JP2018008953A/ja not_active Withdrawn
- 2017-09-06 AU AU2017225039A patent/AU2017225039B2/en not_active Ceased
- 2017-12-25 JP JP2017247383A patent/JP2018070648A/ja not_active Withdrawn
-
2018
- 2018-03-20 US US15/926,035 patent/US10994008B2/en active Active
-
2020
- 2020-12-11 CY CY20201101173T patent/CY1123647T1/el unknown
- 2020-12-21 HR HRP20202042TT patent/HRP20202042T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123647T1 (el) | Διαμορφωση της ανοσιας ογκων | |
CL2016001586A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
UY35464A (es) | Inhibidores covalentes de kras g12c. | |
MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
MX2015012054A (es) | Inhibidores covalentes de kras g12c. | |
CL2015002807A1 (es) | Terapia de combinación | |
DK3043763T3 (da) | Stimulerings- og behandlingsindretning | |
DK2964327T3 (da) | Anordninger og fremgangsmåder til multifokal ultralydsterapi | |
DK3027208T3 (da) | Cancerdiagnose og -terapi, der involverer cancerstamceller | |
AU352731S (en) | Safety apparatus | |
MX2016016667A (es) | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. | |
UY4314Q (es) | Configuracion aplicada en zapato | |
TH182669B (th) | วิธีการบำบัดโรคมะเร็งโดยการใช้ตัวยับยั้ง tigit และสารต้านโรคมะเร็ง | |
TWD158466S (zh) | 電位治療器 | |
AU362279S (en) | Exercise device | |
AU347116S (en) | Footing plate | |
AU347114S (en) | Footing plate | |
AU347117S (en) | Footing plate | |
AU347113S (en) | Footing plate | |
AU347115S (en) | Footing plate | |
AU359208S (en) | Barrier rail | |
TH1501007670A (th) | การใช้โมเลกุลที่ยับยั้งเซมาโฟริน-4D(semaphorin-4D) ในการรวมกับสารรักษาโรคที่ปรับเปลี่ยนภูมิคุ้มกันในการยับยั้งการโตของเนื้องอก และการแพร่กระจายของเนื้อร้าย(metastases) | |
AU356698S (en) | Chair | |
AU356775S (en) | Chair | |
AU348490S (en) | Hole saver |